A detailed history of Cetera Investment Advisers transactions in Precigen, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 260,312 shares of PGEN stock, worth $195,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
260,312
Previous 267,812 2.8%
Holding current value
$195,234
Previous $423,000 41.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.91 - $1.88 $6,825 - $14,100
-7,500 Reduced 2.8%
260,312 $247,000
Q2 2024

Aug 22, 2024

BUY
$1.27 - $1.75 $9,271 - $12,775
7,300 Added 2.8%
267,812 $423,000
Q1 2024

May 24, 2024

BUY
$1.21 - $1.75 $315,219 - $455,896
260,512 New
260,512 $377,000
Q4 2023

Feb 13, 2024

BUY
$0.89 - $1.41 $9,567 - $15,157
10,750 Added 4.46%
251,575 $337,000
Q3 2023

Nov 14, 2023

BUY
$1.08 - $1.85 $4,320 - $7,400
4,000 Added 1.69%
240,825 $341,000
Q2 2023

Aug 09, 2023

BUY
$0.96 - $1.4 $3,360 - $4,900
3,500 Added 1.5%
236,825 $272,000
Q1 2023

May 15, 2023

BUY
$0.88 - $2.19 $62,568 - $155,709
71,100 Added 43.83%
233,325 $247,000
Q4 2022

Feb 14, 2023

BUY
$1.27 - $2.26 $1,841 - $3,276
1,450 Added 0.9%
162,225 $246,000
Q3 2022

Nov 10, 2022

BUY
$1.41 - $2.79 $1,128 - $2,232
800 Added 0.5%
160,775 $341,000
Q2 2022

Aug 11, 2022

BUY
$1.15 - $2.53 $11,830 - $26,026
10,287 Added 6.87%
159,975 $214,000
Q1 2022

May 13, 2022

BUY
$1.91 - $3.98 $57,414 - $119,638
30,060 Added 25.13%
149,688 $316,000
Q4 2021

Feb 14, 2022

BUY
$3.53 - $5.5 $251,420 - $391,732
71,224 Added 147.14%
119,628 $444,000
Q3 2021

Nov 16, 2021

BUY
$4.99 - $6.55 $241,535 - $317,046
48,404 New
48,404 $242,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $156M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.